Topoisomerase II beta expression level correlates with doxorubicin-induced apoptosis in peripheral blood cells

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 374, Issue 1, 2006, Pages 21-30

  Kersting, Gisela ^a   Tzvetkov, Mladen V ^a   Huse, Klaus ^b   Kulle, Bettina ^a   Hafner, Verena ^a   Brockmöller, Jürgen ^a   Wojnowski, Leszek ^c  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b FRITZ LIPMANN INSTITUTE   (Germany)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Apoptosis; Doxorubicin; Peripheral blood lymphocytes; SNP; TOP2B; Topoisomerase II

Indexed keywords

ANTINEOPLASTIC ANTIBIOTIC; DNA BINDING PROTEIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE II BETA; DOXORUBICIN; MESSENGER RNA;

APOPTOSIS; ARTICLE; BLOOD; CATALYSIS; DRUG EFFECT; FEMALE; GENETICS; GENOTYPE; HUMAN; MALE; METABOLISM; PHENOTYPE;

ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; CATALYSIS; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; DOXORUBICIN; FEMALE; GENOTYPE; HUMANS; MALE; PHENOTYPE; RNA, MESSENGER;

EID: 39049180715     PISSN: 00281298     EISSN: 14321912     Source Type: Journal    
DOI: 10.1007/s00210-006-0091-0     Document Type: Article

References (40)

1. Akimitsu N, Adachi N et al (2003). Enforced cytokinesis without complete nuclear division in embryonic cells depleting the activity of DNA topoisomerase IIalpha. Genes Cells 8:393-402 (Pubitemid 36504014)
2. Austin CA, Marsh KL (1998) Eukaryotic DNA topoisomerase II beta. Bioessays 20:215-226
3. Barrett JC, Fry B et al (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21:263-265 (Pubitemid 40202029)
4. Bielack SS, Erttmann R et al (1996). Impact of scheduling on toxicity and clinical efficacy of doxorubicin: what do we know in the mid-nineties? Eur J Cancer 32A:1652-1660 (Pubitemid 26306872)
5. Bonfield JK, Smith K et al (1995) A new DNA sequence assembly program. Nucleic Acids Res 23:4992-4999 (Pubitemid 26012480)
6. Boyum A (1984) Separation of lymphocytes, granulocytes, and monocytes from human blood using iodinated density gradient media. Methods Enzymol 108:88-102
7. Breidenthal SE, White DJ et al (2004) Identification of genetic variants in the neuronal form of tryptophan hydroxylase (TPH2). Psychiatr Genet 14:69-72 (Pubitemid 38766412)
8. Brown GA, McPherson JP et al (1995) Relationship of DNA topoisomerase II alpha and beta expression to cytotoxicity of antineoplastic agents in human acute lymphoblastic leukemia cell lines. Cancer Res 55:78-82
9. Capranico G, Tinelli S et al (1992) Different patterns of gene expression of topoisomerase II isoforms in differentiated tissues during murine development. Biochim Biophys Acta 1132:43-48
10. Cargill M, Altshuler D et al (1999). Characterization of single-nucleotide polymorphisms in coding regions of human genes. Nat Genet 22:231-238 (Pubitemid 29297248)
11. Ciobotaro P, Drucker L et al (2003) The effects of doxorubicin on apoptosis and adhesion molecules of normal peripheral blood leukocytes-an ex vivo study. Anticancer Drugs 14:383-389 (Pubitemid 36683751)
12. Dunkern TR, Wedemeyer I et al (2003) Resistance of p53 knockout cells to doxorubicin is related to reduced formation of DNA strand breaks rather than impaired apoptotic signaling. DNA Repair (Amst) 2:49-60 (Pubitemid 35435438)
13. Durbecq V, Paesmans M et al (2004) Topoisomerase-II alpha expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel. Mol Cancer Ther 3:1207-1214 (Pubitemid 39440165)
14. Ewing B, Green P (1998) Base-calling of automated sequencer traces using phred. II. Error probabilities. Genome Res 8:186-194 (Pubitemid 28177230)
15. Ewing B, Hillier L et al (1998) Base-calling of automated sequencer traces using phred. I. Accuracy assessment. Genome Res 8:175-185 (Pubitemid 28177229)
16. Ferraro C, Quemeneur L et al (2000) Anthracyclines trigger apoptosis of both G0-G1 and cycling peripheral blood lymphocytes and induce massive deletion of matur T and B cells. Cancer Res 60:1901-1907 (Pubitemid 30207650)
17. Fortune JM, Osheroff N (2000) Topoisomerase II as a target for anticancer drugs: when enzymes stop being nice. Prog Nucleic Acid Res Mol Biol 64:221-253
18. Freidlin B, Zheng G et al (2002) Trend tests for case-control studies of genetic markers: power, sample size and robustness. Hum Hered 53:146-152
19. Gabriel SB, SF Schaffner et al (2002) The structure of haplotype blocks in the human genome. Science 296:2225-2229 (Pubitemid 34680308)
20. Gewirtz DA (1999) A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 57:727-741
21. Glatt CE, DeYoung JA et al (2001) Screening a large reference sample to identify very low frequency sequence variants: comparisons between two genes. Nat Genet 27:435-438 (Pubitemid 32268427)
22. Glatt CE, Tampilic M et al (2004) Re-screening serotonin receptors for genetic variants identifies population and molecular genetic complexity. Am J Med Genet B Neuropsychiatr Genet 124:92-100 (Pubitemid 38031600)
23. Kalow W, Endrenyi L et al (1999) Repeat administration of drugs as a means to assess the genetic component in pharmacological variability. Pharmacology 58:281-284 (Pubitemid 29206182)
24. Kaufmann SH, Karp JE et al (1994) Topoisomerase II levels and drug sensitivity in adult acute myelogenous leukemia. Blood 83:517-530 (Pubitemid 24030580)
25. Klumper E, Giaccone G et al (1995) Topoisomerase II alpha gene expression in childhood acute lymphoblastic leukemia. Leukemia 9:1653-1660
26. Koch I, Weil R et al (2002) Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA. Drug Metab Dispos 30:1108-1114
27. Koshiyama M, Fujii H et al (2001) Correlation between Topo II alpha expression and chemosensitivity testing for Topo II-targeting drugs in gynaecological carcinomas. Anticancer Res 21:905-910 (Pubitemid 32494188)
28. Lang AJ, Mirski SE et al (1998) Structural organization of the human TOP2A and TOP2B genes. Gene 221:255-266 (Pubitemid 29023753)
29. Leabman MK, Huang CC et al (2003) Natural variation in human membrane transporter genes reveals evolutionary and functional constraints. Proc Natl Acad Sci USA 100:5896-5901 (Pubitemid 36576904)
30. Lok CN, Lang AJ et al (2002) Characterization of the human topoisomerase IIbeta (TOP2B) promoter activity: essential roles of the nuclear factor-Y (NF-Y)- and specificity protein-1 (Sp1)-binding sites. Biochem J 368:741-751 (Pubitemid 36042675)
31. Meyer KN, Kjeldsen E et al (1997) Cell cycle-coupled relocation of types I and II topoisomerases and modulation of catalytic enzyme activities. J Cell Biol 136:775-788 (Pubitemid 27098735)
32. Miller KG, Liu LF et al (1981) A homogeneous type II DNA topoisomerase from HeLa cell nuclei. J Biol Chem 256:9334-9339
33. Muller MT, Helal K et al (1989) A rapid and quantitative microtiter assay for eukaryotic topoisomerase II. Nucleic Acids Res 17:9499 (Pubitemid 20003233)
34. Nickerson DA, Taylor SL et al (2000) Sequence diversity and large-scale typing of SNPs in the human apolipoprotein E gene. Genome Res 10:1532-1545
35. Osheroff N, Zechiedrich EL et al (1991) Catalytic function of DNA topoisomerase II. Bioessays 13:269-273
36. Padget K, Pearson AD et al (2000) Quantitation of DNA topoisomerase IIalpha and beta in human leukaemia cells by immunoblotting. Leukemia 14:1997-2005
37. Stephens M, Smith NJ et al (2001) A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 68:978-989 (Pubitemid 32289743)
38. Turley H, Comley M et al (1997) The distribution and expression of the two isoforms of DNA topoisomerase II in normal and neoplastic human tissues. Br J Cancer 75:1340-1346 (Pubitemid 27179826)
39. Woessner RD, Mattern MR et al (1991) Proliferation- and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells. Cell Growth Differ 2:209-214
40. Yang X, Li W et al (2000) DNA topoisomerase IIbeta and neural development. Science 287:131-134 (Pubitemid 30033236)